GERMANTOWN, Md., Jan. 17, 2018 /PRNewswire/ -- Intrexon
Corporation (NYSE: XON) announced today that it has priced its
previously announced underwritten public offering of common stock
consisting of 6,000,000 shares at a public offering price of
$12.50 per share. In addition,
Intrexon has granted the underwriters a 30-day option to purchase
up to an additional 900,000 shares of common stock offered in the
public offering.
The offering is expected to close on January 19, 2018,
subject to customary closing conditions. Gross proceeds to Intrexon
from the offering are expected to be approximately $75 million before deducting the underwriting
discount and other offering expenses payable by Intrexon and
excluding any exercise of the underwriters' option.
JMP Securities LLC is acting as sole book-running manager and
Stifel is acting as lead manager for the offering. Northland
Capital Markets is acting as co-manager.
The public offering is being made pursuant an automatic shelf
registration statement on Form S-3 that was previously filed with
the Securities and Exchange Commission (SEC) and became effective
on September 1, 2017. A final
prospectus supplement relating to the offering will be filed with
the SEC and will be available on the website of the SEC
at www.sec.gov. When available, copies of the final prospectus
supplement and accompanying base prospectus relating to the
offering may also be obtained from JMP Securities LLC, 600
Montgomery Street, Suite 1100, San Francisco, California 94111, Attention: Prospectus
Department, by calling +1 (415) 835-8985, or by email at
syndicate@jmpsecurities.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
About Intrexon Corporation
Intrexon Corporation (NYSE:
XON) is Powering the Bioindustrial Revolution with Better
DNA™ to create biologically-based products that improve the
quality of life and the health of the planet. Intrexon's
integrated technology suite provides its partners across diverse
markets with industrial-scale design and development of complex
biological systems delivering unprecedented control, quality,
function, and performance of living cells.
Trademarks
Intrexon and Powering the Bioindustrial
Revolution with Better DNA, and Better DNA are trademarks of
Intrexon and/or its affiliates. Other names may be trademarks of
their respective owners.
Forward-Looking Safe Harbor Statement
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, which
involve risks and uncertainties, including statements regarding the
proposed public offering. Various factors may cause differences
between Intrexon's expectations and actual results, including risks
and uncertainties associated with market conditions and the
satisfaction of customary closing conditions related to the
proposed offering. More information about potential factors that
could affect Intrexon's business and financial results is contained
in its annual report on Form 10-K, its quarterly reports on Form
10-Q and other filings with the SEC. Intrexon does not intend, and
undertakes no duty, to update this information to reflect future
events or circumstances.
For more information about Intrexon Corporation,
contact:
Investor Contact:
Thomas Shrader, PhD
Vice President, Communications & Strategy
investors@intrexon.com
Corporate Contact:
Marie Rossi, PhD
Director, Technical Communications
Tel: +1 (301) 556-9850
publicrelations@intrexon.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/intrexon-prices-public-offering-of-common-stock-300583874.html
SOURCE Intrexon Corporation